TherapeuticsMD, Inc.
TXMDHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 23, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, TherapeuticsMD, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. The company carries a $21.4M market cap, placing it firmly in the micro-cap category. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Market Cap
$21.4M
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
5.29
EPS (TTM)
$-0.04
EPS (Fwd)
$0.35
ROE
-1.1%
ROA
-2.9%
Cash
$9.2M
Total Debt
$5.6M
Free CF
$896,625
52W Change
41.2%
Annual Financials
Cash vs Debt
Where TXMD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TXMD finished 10.58% below its 150-day moving average ($2.08) and 12.26% below its 200-day moving average ($2.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TXMD overbought or oversold?
At the October 20, 2026 close, TXMD's RSI(14) was 26.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $9.2M in cash and $5.6M in debt, TXMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $897K, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -1.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $70.0M to $3.0M.
The relatively low beta of 0.65 suggests TXMD is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TXMD.